Haemoglobin A1c: difference between revisions
Diff·revision 14 → 15·03:15, 3 Jun 2025
Difference between revision 14 and revision 15 of Haemoglobin A1c. 6 lines changed; the page grew by 700 bytes.
| Revision 14 — 13:48, 3 May 2025 RegainRomilly (talk) clarify that the marker is method-dependent and not comparable across platforms 3,396 bytes +30 | Revision 15 — 03:15, 3 Jun 2025 B12_Bettina (talk) split the analytical performance from the clinical interpretation 4,096 bytes +700 | ||
|---|---|---|---|
| 34 | Where HbA1c is unreliable, fructosamine or continuous glucose monitoring metrics provide alternatives measuring different windows.{{r|nathan2008}} | 34 | Where HbA1c is unreliable, fructosamine or continuous glucose monitoring metrics provide alternatives measuring different windows.{{r|nathan2008}} |
| 35 | 35 | ||
| + | 36 | == Use in this field == | |
| + | 37 | HbA1c is the primary glycaemic endpoint in essentially every type 2 diabetes trial discussed on this wiki, including the [[SUSTAIN trial programme|SUSTAIN]] and [[SURPASS trial programme|SURPASS]] programmes. Reductions of 1–2.5 percentage points are the range these agents produce.{{r|drucker2018}} | |
| + | 38 | ||
| + | 39 | Because the measure integrates over months, a trial cannot demonstrate a glycaemic effect faster than the analyte can move, which is why glycaemic trials run at least six months.{{r|ada2024}} | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |
| 38 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 43 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| 39 | <ref name="nathan2008">Nathan DM, Kuenen J, Borg R, et al. "Translating the A1C assay into estimated average glucose values." ''Diabetes Care'' 31(8):1473–1478 (2008). PMID 18540046.</ref> | 44 | <ref name="nathan2008">Nathan DM, Kuenen J, Borg R, et al. "Translating the A1C assay into estimated average glucose values." ''Diabetes Care'' 31(8):1473–1478 (2008). PMID 18540046.</ref> |
| + | 45 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 46 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 41 | 47 |